ARTICLE | Clinical News
Recentin cediranib: Phase III data
March 15, 2010 7:00 AM UTC
Top-line data from the double-blind, international Phase II/III HORIZON III trial in first-line mCRC patients showed that 20 mg Recentin plus FOLFOX missed the primary endpoint of non-inferiority to 5...